



Supporting Information

Supplementary material

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Lamba G, Esler D, Zhao Y, et al. A retrospective cross-sectional analysis of the economic impact of environmental risk factors on inpatient hospital separations in the Northern Territory. *Med J Aust* 2025; doi: 10.5694/mja2.70053.

SECTION 1

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-7
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	7
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 3 (19)

		(b) Indicate number of participants with missing data for each variable of interest	Table 3 (19)
Outcome data	15*	Report numbers of outcome events or summary measures	Tables 1-3 (17-19)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	n/a
		(b) Report category boundaries when continuous variables were categorized	Table 3 (19)
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Figure 2 (21)
Discussion			
Key results	18	Summarise key results with reference to study objectives	10-11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	In submission system

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

SECTION 2 - ICD-10-AM and NTEAF mapping

ICD code name	ICD code description	Category	Water quality, sanitation and hygiene	Home condition	Indoor air pollution	Built environment and land use	Non-occupational non-domestic chemical exposure	Recreational environment	Climate	Public water resources	Outdoor air pollution	Radiation	Environmental noise	Occupational factors	Total
L00	Staphylococcal scalded skin syndrome	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
L01	Impetigo	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
L02	Cutaneous abscess, furuncle and carbuncle	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
L03	Cellulitis	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
L04	Acute lymphadenitis	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
L08.0	Pyoderma	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
L08.8	Other specified local infections of skin and subcutaneous tissue	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100

L08.9	Local infection of skin and subcutaneous tissue, unspecified	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
B87	Fly infestation - wound myiasis	Skin infection incl. pustules, abscess, cellulitis, impetigo	60	25					15						100
B86	Scabies	Scabies	25	70											95
W53	Bitten by rat	Mammal bite		25		50		10	5					5	95
W54	Bitten or struck by dog	Mammal bite		25		50		10	5					5	95
W55	Bitten or struck by other mammals	Mammal bite		25		50		10	5					5	95
X30	Exposure to excessive natural heat	Natural exposure		25		50		10	5					5	95
X31	Exposure to excessive natural cold	Natural exposure		25		50		10	5					5	95
X32	Exposure to sunlight	Natural exposure		25		50		10	5					5	95
X37	Victim of cataclysmic storm	Natural exposure		25		50		10	5					5	95
X38	Victim of flood	Natural exposure		25		50		10	5					5	95
X39	Exposure to other and unspecified forces of nature	Natural exposure		25		50		10	5					5	95
C43	Melanoma and other malignant neoplasms of skin	Skin cancer										95			95
C44	Melanoma and other malignant neoplasms of skin	Skin cancer										95			95
D22	Melanocytic naevi	Skin cancer										95			95

[illegible]

[illegible]

W65	Accidental drowning and submersion	Drowning				30		30	5					1	66
W66	Accidental drowning and submersion	Drowning				30		30	5					1	66
W67	Accidental drowning and submersion	Drowning				30		30	5					1	66
W68	Accidental drowning and submersion	Drowning				30		30	5					1	66
W69	Accidental drowning and submersion	Drowning				30		30	5					1	66
W70	Accidental drowning and submersion	Drowning				30		30	5					1	66
W73	Accidental drowning and submersion	Drowning				30		30	5					1	66
W74	Accidental drowning and submersion	Drowning				30		30	5					1	66
T75.1	Drowning and nonfatal submersion	Drowning				30		30	5					1	66
I05	Chronic rheumatic heart diseases	RHD	40	25											65
I06	Chronic rheumatic heart diseases	RHD	40	25											65
I07	Chronic rheumatic heart diseases	RHD	40	25											65
I08	Chronic rheumatic heart diseases	RHD	40	25											65
I09	Chronic rheumatic heart diseases	RHD	40	25											65
W01	Fall on same level from	Fall		25		10		20						5	60

[illegible]

I20	Ischaemic heart diseases	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I21	Ischaemic heart diseases	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I22	Ischaemic heart diseases	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I23	Ischaemic heart diseases	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I24	Ischaemic heart diseases	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I25	Ischaemic heart diseases	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I33	Acute and subacute endocarditis	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I34	Nonrheumatic mitral valve disorders	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I35	Nonrheumatic aortic valve disorders	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I36	Nonrheumatic tricuspid valve disorders	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I37	Pulmonary valve disorders	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
I38	Endocarditis, valve unspecified	Cardiovascular disease (not RHD)		5	3	30		5	3					10	56
J45	Asthma	Asthma		5	40	2					5				52
J46	Asthma	Asthma		5	40	2					5				52
J09	Influenza and pneumonia	Lower Respiratory tract infections		10	30	2					5				47
J10	Influenza and pneumonia	Lower Respiratory tract infections		10	30	2					5				47

[illegible]

[illegible]

Y09	Assault	Assault		20		5									25
X40	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X41	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X42	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X43	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X44	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X45	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X46	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X47	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
X48	Accidental poisoning by and exposure to	Poisonings		10			5							5	20

	noxious substances														
X49	Accidental poisoning by and exposure to noxious substances	Poisonings		10			5							5	20
T51	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T52	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T53	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T54	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T55	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T56	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T57	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20

T58	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T59	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T60	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T61	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T62	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T63	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T64	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
T65	Toxic effects of substances chiefly nonmedicinal as to source	Poisonings		10			5							5	20
J40	Chronic lower respiratory diseases	Chronic lung disease			10						1			1	12

[illegible]

[illegible]

[illegible]